Healthcare / Diagnostics & ResearchTSXV
$0.01
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-2.6M · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1M
P/E
N/A
•EV/EBITDA
N/A
•ROE
27.3%
↑Gross Margin
83.9%
↑Debt/Equity
-1.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-61.8%
FCF CAGR
—
FCF margin
-211.9%
FCF / Net income
0.61x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $605709.0 · net income $-2.1M · FCF $-1.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $605709.00 | $605709.00 | $5.5M | $6.7M | $10.9M |
| Net Income | $-2.1M | $-2.1M | $1.4M | $-8.7M | $-8.0M |
| EBITDA | $-993476.00 | $-993476.00 | $2.5M | $-7.7M | $-7.3M |
| EPS | -0.02 | -0.02 | 0.01 | -0.10 | -0.11 |
| Gross Margin | 83.9% | 83.9% | 61.7% | 26.8% | 54.3% |
| Operating Margin | -424.8% | -424.8% | -68.8% | -113.6% | -35.6% |
| Net Margin | -349.3% | -349.3% | 24.7% | -129.9% | -73.9% |
| Balance Sheet | |||||
| Debt/Equity | -1.10 | -1.10 | -1.18 | -0.76 | -5.08 |
| Current Ratio | 0.05 | 0.05 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.3M | $-1.3M | $-2.6M | $-4.5M | $-1.7M |
| Returns | |||||
| ROE | 27.3% | 27.3% | -21.0% | 84.0% | 506.0% |
| Valuation | |||||
| P/E | — | — | 10.00 | — | — |
| EV/EBITDA | — | — | 7.22 | — | — |
| Growth & Yield | |||||
| Revenue Growth | -89.0% | -89.0% | -17.4% | -38.7% | — |
| EPS Growth | -300.0% | -300.0% | 110.0% | 9.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-85.7%
Start / end P/E
n/dx → n/dx
EPS bridge
0.01 → -0.02
Residual
-85.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.